Please use this identifier to cite or link to this item: https://hdl.handle.net/1959.11/16267
Title: Differences in major depressive disorder and generalised anxiety disorder symptomatology between prostate cancer patients receiving hormone therapy and those who are not
Contributor(s): Sharpley, Christopher  (author)orcid ; Bitsika, Vicki  (author); Wootten, Addie (author); Christie, David R H  (author)
Publication Date: 2014
DOI: 10.1002/pon.3566
Handle Link: https://hdl.handle.net/1959.11/16267
Abstract: Objective: The aim of this study is to explore the associations between hormone treatment variables and depression, and the nature of depression in prostate cancer (PCa) patients by comparing the severity and symptom profile of anxiety and depression in men who were currently receiving hormone therapy (HT) versus those who were not. Method: Self-reports of anxiety and depression on standardized scales of GAD and major depressive disorder (MDD) were collected from 156 PCa patients across two recruitment sites in Australia. Patients who were currently receiving HT were compared with patients not receiving HT for their severity and symptom profiles on GAD and MDD. Results: Participants receiving HT had significantly higher GAD and MDD total scores than patients who were not receiving HT. In addition, the symptom profiles of these two HT subgroups were differentiated by significantly higher scores on the key criteria for GAD and MDD plus fatigue and sleeping difficulties but not the remaining symptoms of GAD and MDD. However, there were no significant differences between HT subgroups for the degree of functional impairment experienced by these symptoms. Conclusion: Although these data confirm the association between HT and anxiety/depression, the range of GAD and MDD symptoms influenced is relatively restricted. Moreover, functional ability does not appear to be impaired by HT. These findings clarify the ways in which HT affects PCa patients and suggests that a simple total scale score for anxiety and depression may not be as helpful in designing treatment as consideration of the symptomatic profiles of PCa patients receiving HT.
Publication Type: Journal Article
Source of Publication: Psycho-Oncology, 23(12), p. 1350-1355
Publisher: John Wiley & Sons Ltd
Place of Publication: United Kingdom
ISSN: 1057-9249
1099-1611
Field of Research (FOR): 110903 Central Nervous System
Socio-Economic Outcome Codes: 920111 Nervous System and Disorders
Peer Reviewed: Yes
HERDC Category Description: C1 Refereed Article in a Scholarly Journal
Statistics to Oct 2018: Visitors: 253
Views: 256
Downloads: 0
Appears in Collections:Journal Article

Files in This Item:
2 files
File Description SizeFormat 
Show full item record

SCOPUSTM   
Citations

11
checked on Nov 26, 2018

Page view(s)

136
checked on May 2, 2019
Google Media

Google ScholarTM

Check

Altmetric


Items in Research UNE are protected by copyright, with all rights reserved, unless otherwise indicated.